American Society of Hematology

SHERPA: Blue

People

  1. Zelenetz
    Zelenetz
  2. Horwitz
    Horwitz
  3. Palomba
    Palomba
  4. Noy
    Noy
  5. Moskowitz
    Moskowitz
  6. Hamlin
    Hamlin
  7. Kumar
    Kumar
  8. Salles
    Salles
  9. Yahalom
    Yahalom
  10. Dogan
    Dogan

Groups

  1. Center for Hematologic Malignancies (895)
  2. Department of Medicine (895)
  3. Hematologic Malignancies, Division of (895)
  4. Lymphoma (895)
  5. Population Sciences Research Program (271)
  6. Survivorship Research (228)
  7. Epidemiology and Biostatistics (142)
  8. Executive Committee, Center for Hematologic Malignancies (126)
  9. GSK Faculty (121)
  10. Biostatistics Service (117)
Search Within
  1. "Lymphoma"
Formats
  1. Meeting Abstract (719)
  2. Journal Article (150)
  3. Review (9)
  4. Research Letter (8)
  5. Editorial (5)
  6. Guidelines (3)
  7. Correspondence (1)
Groups
  1. Center for Hematologic Malignancies (895)
  2. Department of Medicine (895)
  3. Hematologic Malignancies, Division of (895)
  4. Lymphoma (895)
  5. Population Sciences Research Program (271)
  6. Survivorship Research (228)

More Groups

People
  1. Andrew Zelenetz (327)
  2. Steven Horwitz (258)
  3. Maria Palomba (181)
  4. Ariela Noy (163)
  5. Alison Moskowitz (154)
  6. Craig Moskowitz (128)

More People

Years
  1. 2025 (5)
  2. 2024 (27)
  3. 2023 (87)
  4. 2022 (61)
  5. 2021 (66)
  6. 2020 (52)

More Years

Publications
  1. Blood (830)
  2. Blood Advances (56)
  3. Hematology-American Society of Hematology Education Program (9)

Results (895)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Retrospective analysis of gemcitabine and oxaliplatin (GemOx)-based treatment in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma
    Meeting Abstract

    Schade, J. R.; Kim, C.; Drill, E.; Qiu, A.; Batlevi, C. L.; Caron, P.; Colbourn, D. S.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Belinostat induces high overall response rate (ORR) in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma (AITL)
    Meeting Abstract

    Sawas, A.; Ma, H.; Shustov, A.; Hsu, P.; Bhat, G.; Acosta, M.; Horwitz, S. M.; O'Connor, O. A.
    Blood (2019)

    Fulltext@MSK | Save
  • A randomized trial of EPOCH-based chemotherapy with vorinostat for highly aggressive HIV-associated lymphomas: Updated results evaluating impact of diagnosis-to-treatment interval (DTI) and pre-protocol systemic therapy on outcomes
    Meeting Abstract

    Ramos, J. C.; Sparano, J.; Moore, P. C.; Siegel, E.; Lee, J. Y.; Reid, E. G.; Ambinder, R. F.; Chadburn, A.; Rubinstein, P. G.; Durand, C.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Response-adapted therapy with infusional EPOCH chemotherapy plus rituximab in HIV-associated, B-cell non-Hodgkin's lymphoma
    Meeting Abstract

    Ramos, J. C.; Ambinder, R. F.; Sparano, J.; Lee, J. Y.; Kaplan, L. D.; Wachsman, W.; Aboulafia, D. M.; Noy, A.; Ratner, L.; Henry, D. H.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Comparing gradings of immune effector cells toxicities: Application of ASTCT consensus grading system and implications for clinical management
    Meeting Abstract

    Pennisi, M.; Jain, T.; Mead, E.; Santomasso, B.; Silverberg, M. L.; Batlevi, Y.; Shouval, R.; Maloy, M. A.; Devlin, S. M.; Batlevi, C. L.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • EASIX and modified-EASIX are early predictors of severe cytokine release syndrome and neurotoxicity in patients treated with chimeric antigen receptor T cells
    Meeting Abstract

    Pennisi, M.; Sanchez-Escamilla, M.; Flynn, J.; Maloy, M. A.; Silverberg, M. L.; Batlevi, Y.; Shouval, R.; Batlevi, C. L.; Brentjens, R. J.; Devlin, S. M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • A phase II clinical trial of CPI-613 (devimistat) in patients with relapsed or refractory burkitt lymphoma/leukemia or high-grade B-cell lymphoma with rearrangements of MYC and BCL2and/or BCL6
    Meeting Abstract

    Noy, A.; Pardee, T. S.; Nikolaenko, L.; Steiner, R. E.; Abramson, J. S.; Dunleavy, K.; Luther, S.
    Blood (2019)

    Fulltext@MSK | Save
  • Long-term follow-up confirms durability of single-agent brentuximab vedotin as pre-transplant salvage for classical Hodgkin lymphoma
    Meeting Abstract

    Moskowitz, A. J.; Schoder, H.; Lee, J.; Davey, T.; Hancock, H.; Hamlin, P. A.; Horwitz, S. M.; Kumar, A.; Matasar, M. J.; Noy, A.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Final results of a phase II biomarker-driven study of ruxolitinib in relapsed and refractory T-cell lymphoma
    Meeting Abstract

    Moskowitz, A. J.; Ghione, P.; Jacobsen, E. D.; Ruan, J.; Schatz, J. H.; Noor, S.; Myskowski, P.; Hancock, H.; Davey, T.; Obadi, O.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • High complete response rate observed with second-line chemo-immunotherapy with pembrolizumab and GVD (gemcitabine, vinorelbine, and liposomal doxorubicin) in relapsed and refractory classical Hodgkin lymphoma
    Meeting Abstract

    Moskowitz, A. J.; Shah, G. L.; Schoder, H.; Hancock, H.; Davey, T.; Joong, C.; Pomerantz, L.; Jarjies, C.; Kumar, A.; Lahoud, O. B.; more...
    Blood (2019)

    Fulltext@MSK | Save